Cancer, Character, and Calling

Girindra Raval, MD; Anand Jillella, MD, J. Harold Harrison, MD Distinguished University Chair in Medicine, professor, medicine & pediatrics, chief, Division of Hematology/Oncology, Augusta University Medical College of Georgia

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

October 15th 2025

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP

ByGirindra Raval, MD,David A. Frank, MD, PhD, FACP

August 13th 2025

Girindra Raval, MD, and David A. Frank, MD, PhD, FACP, discuss Frank’s journey, through his undergraduate studies at MIT, and completion of an MD/PhD program at Yale University.

Cancer, Character, and Calling: The Oncologist's Journey

Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD

ByGirindra Raval, MD,Jorge Cortes, MD

July 23rd 2025

Drs Raval and Cortes discuss Dr. Cortes’ journey through the hematologic oncology field and highlight ongoing work in the hematologic oncology space.

Cancer, Character, and Calling

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP

Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

Five Under 5: Top Oncology Videos for the Week of 1/25

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma